董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Claudine Bruck | 女 | Director | 64 | 0.51万美元 | 未持股 | 2020-01-30 |
| Maria Maccecchini | 女 | Founder, President and CEO and director | 69 | 12.00万美元 | 未持股 | 2020-01-30 |
| Michael Hoffman | 男 | Chairman of the Board | 69 | 0.51万美元 | 未持股 | 2020-01-30 |
| Robert Whelan | 男 | Director | 67 | 0.51万美元 | 未持股 | 2020-01-30 |
| Mark White | 男 | Director | 63 | 0.51万美元 | 未持股 | 2020-01-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Maria Maccecchini | 女 | Founder, President and CEO and director | 69 | 12.00万美元 | 未持股 | 2020-01-30 |
| Jeffrey McGroarty | 男 | Chief Financial Officer | 50 | 15.52万美元 | 未持股 | 2020-01-30 |
董事简历
中英对照 | 中文 | 英文- Claudine Bruck
-
Claudine Bruck博士自2018年3月起担任Navidea的董事。Bruck博士自2016年6月起担任Proliagen LLC的联合创始人兼首席执行官，该公司是一家新兴公司，致力于开发基于microRNA的组织再生药物。她也是宾夕法尼亚大学转化医学和应用技术研究所（University of Pennsylvania&8217；s Institute of Translational Medicine and Applied Technology）的课程主管，以及Sapvax LLC的首席科学官，她是BioMotiv LLC的兼职员工。Bruck博士是AnnovisBio，Inc.董事会成员。ANVS，一家专注于神经退行性疾病药物开发的生物技术公司。Bruck博士于1985年加入葛兰素史克（GlaxoSmithKline），负责建立GSK&；8217；S艾滋病疫苗项目。Bruck博士在GSK&8217；s Vaccine Group担任职务时，在GSK&8217；s HPV Vaccine（Cervarix）的开发中发挥了重要作用，并在加入GSK的药物发现小组之前从一开始到第二阶段领导他们的癌症疫苗计划。她曾担任药物发现集团的多种职务，从临床免疫学主管（2004年至2005年），到外部药物发现卓越中心的副总裁兼生物学主管（2005年至2008年），到副总裁兼新成立的眼科研发集团的负责人（2008年至2015年）。Bruck博士拥有布鲁塞尔大学（University of Brussels）生物化学博士学位。
Claudine Bruck has served as a director of Navidea since March 2018. Dr. Bruck is co-founder and has served as Chief Executive Officer of Prolifagen LLC, a start-up company developing a microRNA-based medicine for tissue regeneration, since June 2016. She is also a course director at University of Pennsylvania’s Institute of Translational Medicine and Applied Technology, and Chief Scientific Officer of SAPVAX LLC for which she is a half-time employee to BioMotiv LLC. Dr Bruck is a member of the board of directors of Annovis Bio, Inc. ANVS, a biotechnology company focused on development of medicines for neurodegenerative diseases. Dr. Bruck joined GlaxoSmithKline (“GSK”) in 1985 to build GSK’s HIV vaccine program. In her role in GSK’s vaccine group, Dr. Bruck was instrumental in the development of GSK’s HPV vaccine (Cervarix), and headed their cancer vaccine program from inception to Phase 2 before joining the drug discovery group of GSK. She held several roles in the drug discovery group, from Head of Clinical Immunology (2004-2005), to VP and Head of Biology for the Center of Excellence for External Drug Discovery (2005-2008), to VP and Head of a newly formed ophthalmology R&D group (2008-2015). Dr. Bruck holds a Ph.D. in biochemistry from the University of Brussels. - Claudine Bruck博士自2018年3月起担任Navidea的董事。Bruck博士自2016年6月起担任Proliagen LLC的联合创始人兼首席执行官，该公司是一家新兴公司，致力于开发基于microRNA的组织再生药物。她也是宾夕法尼亚大学转化医学和应用技术研究所（University of Pennsylvania&8217；s Institute of Translational Medicine and Applied Technology）的课程主管，以及Sapvax LLC的首席科学官，她是BioMotiv LLC的兼职员工。Bruck博士是AnnovisBio，Inc.董事会成员。ANVS，一家专注于神经退行性疾病药物开发的生物技术公司。Bruck博士于1985年加入葛兰素史克（GlaxoSmithKline），负责建立GSK&；8217；S艾滋病疫苗项目。Bruck博士在GSK&8217；s Vaccine Group担任职务时，在GSK&8217；s HPV Vaccine（Cervarix）的开发中发挥了重要作用，并在加入GSK的药物发现小组之前从一开始到第二阶段领导他们的癌症疫苗计划。她曾担任药物发现集团的多种职务，从临床免疫学主管（2004年至2005年），到外部药物发现卓越中心的副总裁兼生物学主管（2005年至2008年），到副总裁兼新成立的眼科研发集团的负责人（2008年至2015年）。Bruck博士拥有布鲁塞尔大学（University of Brussels）生物化学博士学位。
- Claudine Bruck has served as a director of Navidea since March 2018. Dr. Bruck is co-founder and has served as Chief Executive Officer of Prolifagen LLC, a start-up company developing a microRNA-based medicine for tissue regeneration, since June 2016. She is also a course director at University of Pennsylvania’s Institute of Translational Medicine and Applied Technology, and Chief Scientific Officer of SAPVAX LLC for which she is a half-time employee to BioMotiv LLC. Dr Bruck is a member of the board of directors of Annovis Bio, Inc. ANVS, a biotechnology company focused on development of medicines for neurodegenerative diseases. Dr. Bruck joined GlaxoSmithKline (“GSK”) in 1985 to build GSK’s HIV vaccine program. In her role in GSK’s vaccine group, Dr. Bruck was instrumental in the development of GSK’s HPV vaccine (Cervarix), and headed their cancer vaccine program from inception to Phase 2 before joining the drug discovery group of GSK. She held several roles in the drug discovery group, from Head of Clinical Immunology (2004-2005), to VP and Head of Biology for the Center of Excellence for External Drug Discovery (2005-2008), to VP and Head of a newly formed ophthalmology R&D group (2008-2015). Dr. Bruck holds a Ph.D. in biochemistry from the University of Brussels.
- Maria Maccecchini
-
Maria Maccecchini创立了Annovis，前身为QR Pharma，自2008年5月起担任总裁兼首席执行官。她曾担任Robin Hood Ventures公司（从2002年到2009年）、MidAtlantic Angel Group（从2005年到2009年）的两个天使集团的合伙人兼董事。她于1992年创立Symphony Pharmaceuticals/Annovis公司（生物技术公司，于2001年出售给Transgenomic公司），并担任首席执行官。在此之前，从1987年到1991年，她是Bachem Bioscience（瑞士Bachem AG的美国子公司，Mallinckrodt的分子生物学主管）的总经理。MacCecchini博士在加州理工学院（Caltech）和罗氏免疫学研究所（Roche Institute of Immunology）进行博士后研究。她获得了生物化学博士学位，来自巴塞尔生物中心，并在洛克菲勒大学获得了为期两年的访问奖学金。MacCecchini博士在生物技术公司、促进企业家精神的组织、国际贸易、妇女和慈善组织的几个董事会任职。她自2016年以来一直担任Wharton Business School的讲师。
Maria Maccecchini founded Annovis, formerly QR Pharma, and has served as President and CEO since May 2008. She was partner and director of two angel groups, Robin Hood Ventures, from 2002 to 2009 and MidAtlantic Angel Group, from 2005 to 2009. In 1992 she founded and became chief executive officer of Symphony Pharmaceuticals/Annovis, a biotech company, which was sold in 2001 to Transgenomic. Prior to that, from 1987 to 1991 she was General Manager of Bachem Bioscience, the US subsidiary of Bachem AG, Switzerland and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini conducted post-doctoral research at Caltech and the Roche Institute of Immunology. She earned a Ph.D. in biochemistry is from the Biocenter of Basel with a two-year visiting fellowship at The Rockefeller University. Dr. Maccecchini serves on several boards of biotechnology companies, organizations that promote entrepreneurship, international trade, women and charitable organizations. She has been a lecturer at Wharton Business School since 2016. - Maria Maccecchini创立了Annovis，前身为QR Pharma，自2008年5月起担任总裁兼首席执行官。她曾担任Robin Hood Ventures公司（从2002年到2009年）、MidAtlantic Angel Group（从2005年到2009年）的两个天使集团的合伙人兼董事。她于1992年创立Symphony Pharmaceuticals/Annovis公司（生物技术公司，于2001年出售给Transgenomic公司），并担任首席执行官。在此之前，从1987年到1991年，她是Bachem Bioscience（瑞士Bachem AG的美国子公司，Mallinckrodt的分子生物学主管）的总经理。MacCecchini博士在加州理工学院（Caltech）和罗氏免疫学研究所（Roche Institute of Immunology）进行博士后研究。她获得了生物化学博士学位，来自巴塞尔生物中心，并在洛克菲勒大学获得了为期两年的访问奖学金。MacCecchini博士在生物技术公司、促进企业家精神的组织、国际贸易、妇女和慈善组织的几个董事会任职。她自2016年以来一直担任Wharton Business School的讲师。
- Maria Maccecchini founded Annovis, formerly QR Pharma, and has served as President and CEO since May 2008. She was partner and director of two angel groups, Robin Hood Ventures, from 2002 to 2009 and MidAtlantic Angel Group, from 2005 to 2009. In 1992 she founded and became chief executive officer of Symphony Pharmaceuticals/Annovis, a biotech company, which was sold in 2001 to Transgenomic. Prior to that, from 1987 to 1991 she was General Manager of Bachem Bioscience, the US subsidiary of Bachem AG, Switzerland and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini conducted post-doctoral research at Caltech and the Roche Institute of Immunology. She earned a Ph.D. in biochemistry is from the Biocenter of Basel with a two-year visiting fellowship at The Rockefeller University. Dr. Maccecchini serves on several boards of biotechnology companies, organizations that promote entrepreneurship, international trade, women and charitable organizations. She has been a lecturer at Wharton Business School since 2016.
- Michael Hoffman
-
Michael Hoffman自2014年以来一直担任董事会主席和董事会成员。自2018年以来，他一直担任Stone Capital Partners（私人股本公司，专注于电力和可再生能源）的创始人兼合伙人。从2003年到2018年，霍夫曼先生是Riverstone Holdings LLC或Riverstone的合伙人，主要负责电力和可再生能源的投资。加入Riverstone之前，他曾担任The Blackstone Group L.P.（Blackstone）的高级董事总经理兼并购咨询业务主管，在那里他也曾任职公司的主要集团投资委员会及其执行委员会。在加入Blackstone之前，Hoffman先生是Smith Barney，Harris Upham&Co.的董事总经理兼并购部门的联席主管。霍夫曼先生目前担任OnconovaTherapeutics，Inc.的董事。Hoffman先生还任职于Therapeutic Biotherapeutics，Inc.和Riverstone赞助的各种私人公司的董事会。他的非营利董事会附属机构包括洛克菲勒大学。Hoffman先生在西北大学（Northwestern University）获得学士学位和硕士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Michael Hoffman has served as Chairman of the Board of Directors and a member of our Board of Directors since 2014. Since 2018 he has been the founder and partner at Stone Capital Partners, a private equity firm focused on power and renewable energy. From 2003 to 2018 Mr. Hoffman was a partner of Riverstone Holdings LLC, or Riverstone, where he was principally responsible for investments in power and renewable energy. Before joining Riverstone, Mr. Hoffman was senior managing director and head of the mergers and acquisitions advisory business of The Blackstone Group L.P., or Blackstone, where he also served on the firm's principal group investment committee as well as its executive committee. Prior to joining Blackstone, Mr. Hoffman was managing director and co-head of the mergers and acquisitions department at Smith Barney, Harris Upham & Co. Mr. Hoffman currently serves as a director of Onconova Therapeutics, Inc. Mr. Hoffman also serves on the Board of Directors of Curative Biotherapeutics, Inc. and various private companies sponsored by Riverstone. His non-profit board affiliations include Rockefeller University. Mr. Hoffman received his Bachelor's and Master's Degrees from Northwestern University and his M.B.A. from the Harvard Business School. - Michael Hoffman自2014年以来一直担任董事会主席和董事会成员。自2018年以来，他一直担任Stone Capital Partners（私人股本公司，专注于电力和可再生能源）的创始人兼合伙人。从2003年到2018年，霍夫曼先生是Riverstone Holdings LLC或Riverstone的合伙人，主要负责电力和可再生能源的投资。加入Riverstone之前，他曾担任The Blackstone Group L.P.（Blackstone）的高级董事总经理兼并购咨询业务主管，在那里他也曾任职公司的主要集团投资委员会及其执行委员会。在加入Blackstone之前，Hoffman先生是Smith Barney，Harris Upham&Co.的董事总经理兼并购部门的联席主管。霍夫曼先生目前担任OnconovaTherapeutics，Inc.的董事。Hoffman先生还任职于Therapeutic Biotherapeutics，Inc.和Riverstone赞助的各种私人公司的董事会。他的非营利董事会附属机构包括洛克菲勒大学。Hoffman先生在西北大学（Northwestern University）获得学士学位和硕士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Michael Hoffman has served as Chairman of the Board of Directors and a member of our Board of Directors since 2014. Since 2018 he has been the founder and partner at Stone Capital Partners, a private equity firm focused on power and renewable energy. From 2003 to 2018 Mr. Hoffman was a partner of Riverstone Holdings LLC, or Riverstone, where he was principally responsible for investments in power and renewable energy. Before joining Riverstone, Mr. Hoffman was senior managing director and head of the mergers and acquisitions advisory business of The Blackstone Group L.P., or Blackstone, where he also served on the firm's principal group investment committee as well as its executive committee. Prior to joining Blackstone, Mr. Hoffman was managing director and co-head of the mergers and acquisitions department at Smith Barney, Harris Upham & Co. Mr. Hoffman currently serves as a director of Onconova Therapeutics, Inc. Mr. Hoffman also serves on the Board of Directors of Curative Biotherapeutics, Inc. and various private companies sponsored by Riverstone. His non-profit board affiliations include Rockefeller University. Mr. Hoffman received his Bachelor's and Master's Degrees from Northwestern University and his M.B.A. from the Harvard Business School.
- Robert Whelan
-
Robert Whelan自2016年以来一直担任我们的董事会成员。Whelan先生从2001年开始一直担任Whelan&Company，LLC的总裁，该公司为广泛的公司提供业务与财务咨询与战略服务。Whelan先生于2018年1月1日加入Black Point Partners，Inc.的公司，担任董事总经理，该公司为技术公司提供财务咨询，资本筹集以及并购服务。从2001年到2005年，Whelan先生还担任Valuation Perspects，Inc.的常务董事，这是一家咨询公司。在2001年之前，Whelan先生曾在多家投资银行和经纪公司担任多个高级职位。在其他职位中，Whelan先生是Prudential Volpe Technology Group的副董事长，该公司是Prudential Securities的技术投资银行和研究部门，在此之前，他是Volpe Brown Whelan&Company的首席运营官，董事总经理，投资银行业务主管和董事会成员，一家私人技术和梦百合投资银行、经纪和资产管理公司，于1999年被Prudential Securities收购。Whelan先生担任AspenTechnology，Inc.的董事。该公司是在复杂工业环境中优化资产设计、运营和维护的资产优化解决方案的全球领先供应商，并于2010年4月至2014年9月担任用于治疗侵袭性癌症患者的小分子药物开发商ARIADPharmaceuticals，Inc.的董事。Whelan先生拥有Dartmouth College的历史学学士学位和Stanford University Graduate School of Business的工商管理硕士学位。
Robert Whelan has served as a member of our Board of Directors since 2016. Mr. Whelan has been the President of Whelan & Company, LLC, which provides business and financial consulting and strategic services to a broad range of companies, since 2001. On January 1 2018 Mr. Whelan joined the firm of Black Point Partners, Inc., which provides financial advisory, capital raising and mergers and acquisition services to technology companies, as a managing director. From 2001 to 2005 Mr. Whelan also served as Managing Director of Valuation Perspectives, Inc., a consulting firm. Prior to 2001 Mr. Whelan held a number of senior-level positions at various investment banking and brokerage firms. Among other positions, Mr. Whelan was Vice Chairman of Prudential Volpe Technology Group, the technology investment banking and research division of Prudential Securities, and prior to that, he was Chief Operating Officer, Managing Director, Head of Investment Banking, and a board member of Volpe Brown Whelan & Company, a private technology and healthcare investment banking, brokerage and asset management firm acquired by Prudential Securities in 1999. Mr. Whelan serves as a director of Aspen Technology, Inc.. a leading global supplier of asset optimization solutions that optimize asset design, operations and maintenance in complex, industrial environments, and has served as a director of ARIAD Pharmaceuticals, Inc., a developer of small-molecule drugs to treat patients with aggressive cancers, from April 2010 through September 2014. Mr. Whelan holds a B.A. in History from Dartmouth College and an M.B.A. from Stanford University Graduate School of Business. - Robert Whelan自2016年以来一直担任我们的董事会成员。Whelan先生从2001年开始一直担任Whelan&Company，LLC的总裁，该公司为广泛的公司提供业务与财务咨询与战略服务。Whelan先生于2018年1月1日加入Black Point Partners，Inc.的公司，担任董事总经理，该公司为技术公司提供财务咨询，资本筹集以及并购服务。从2001年到2005年，Whelan先生还担任Valuation Perspects，Inc.的常务董事，这是一家咨询公司。在2001年之前，Whelan先生曾在多家投资银行和经纪公司担任多个高级职位。在其他职位中，Whelan先生是Prudential Volpe Technology Group的副董事长，该公司是Prudential Securities的技术投资银行和研究部门，在此之前，他是Volpe Brown Whelan&Company的首席运营官，董事总经理，投资银行业务主管和董事会成员，一家私人技术和梦百合投资银行、经纪和资产管理公司，于1999年被Prudential Securities收购。Whelan先生担任AspenTechnology，Inc.的董事。该公司是在复杂工业环境中优化资产设计、运营和维护的资产优化解决方案的全球领先供应商，并于2010年4月至2014年9月担任用于治疗侵袭性癌症患者的小分子药物开发商ARIADPharmaceuticals，Inc.的董事。Whelan先生拥有Dartmouth College的历史学学士学位和Stanford University Graduate School of Business的工商管理硕士学位。
- Robert Whelan has served as a member of our Board of Directors since 2016. Mr. Whelan has been the President of Whelan & Company, LLC, which provides business and financial consulting and strategic services to a broad range of companies, since 2001. On January 1 2018 Mr. Whelan joined the firm of Black Point Partners, Inc., which provides financial advisory, capital raising and mergers and acquisition services to technology companies, as a managing director. From 2001 to 2005 Mr. Whelan also served as Managing Director of Valuation Perspectives, Inc., a consulting firm. Prior to 2001 Mr. Whelan held a number of senior-level positions at various investment banking and brokerage firms. Among other positions, Mr. Whelan was Vice Chairman of Prudential Volpe Technology Group, the technology investment banking and research division of Prudential Securities, and prior to that, he was Chief Operating Officer, Managing Director, Head of Investment Banking, and a board member of Volpe Brown Whelan & Company, a private technology and healthcare investment banking, brokerage and asset management firm acquired by Prudential Securities in 1999. Mr. Whelan serves as a director of Aspen Technology, Inc.. a leading global supplier of asset optimization solutions that optimize asset design, operations and maintenance in complex, industrial environments, and has served as a director of ARIAD Pharmaceuticals, Inc., a developer of small-molecule drugs to treat patients with aggressive cancers, from April 2010 through September 2014. Mr. Whelan holds a B.A. in History from Dartmouth College and an M.B.A. from Stanford University Graduate School of Business.
- Mark White
-
Mark White自2016年以来一直担任我们的董事会成员。2014年以来，他一直担任独立顾问，专门从事新产品商业化、营销、业务开发和战略。他曾担任Neurokine Therapeutics公司（专注于神经退行性疾病）的首席执行官（2015年至2016年），以及Neurokappa Therapeutics公司（专注于罕见疾病）的首席执行官。此前，他曾担任Pfizer公司的Vice President、全球营销和其他职务（2002年至2014年），以及Braco Diagnostics公司（放射和心脏病应用诊断制药企业）的营销和业务发展高级主管（1998年至2002年），以及i-Stat公司的业务发展主管，一家医疗器械公司，从1995年到1998年。他持有B.S.和M.ED.拥有密苏里大学的学士学位和芝加哥大学布斯商学院的工商管理硕士学位。
Mark White has served as a member of our Board of Directors since 2016. Since 2014 he has been an independent consultant, specializing in new product commercialization, marketing, business development and strategy. He served as chief executive officer of Neurokine Therapeutics, which focused on neurodegenerative disorders, from 2015-2016 and as chief executive officer of Neurokappa Therapeutics, which focused on rare diseases. Prior to that, he served as vice president, worldwide marketing and other capacities with Pfizer, Inc. from 2002 to 2014 as senior director, marketing and business development with Bracco Diagnostics, a diagnostic pharmaceutical business with radiology and cardiology applications, from 1998-2002 and as director, business development of i-Stat, Inc., a medical device company, from 1995 to 1998. He holds a B.S. and M.Ed. from the University of Missouri and M.B.A. from the University of Chicago Booth School of Business. - Mark White自2016年以来一直担任我们的董事会成员。2014年以来，他一直担任独立顾问，专门从事新产品商业化、营销、业务开发和战略。他曾担任Neurokine Therapeutics公司（专注于神经退行性疾病）的首席执行官（2015年至2016年），以及Neurokappa Therapeutics公司（专注于罕见疾病）的首席执行官。此前，他曾担任Pfizer公司的Vice President、全球营销和其他职务（2002年至2014年），以及Braco Diagnostics公司（放射和心脏病应用诊断制药企业）的营销和业务发展高级主管（1998年至2002年），以及i-Stat公司的业务发展主管，一家医疗器械公司，从1995年到1998年。他持有B.S.和M.ED.拥有密苏里大学的学士学位和芝加哥大学布斯商学院的工商管理硕士学位。
- Mark White has served as a member of our Board of Directors since 2016. Since 2014 he has been an independent consultant, specializing in new product commercialization, marketing, business development and strategy. He served as chief executive officer of Neurokine Therapeutics, which focused on neurodegenerative disorders, from 2015-2016 and as chief executive officer of Neurokappa Therapeutics, which focused on rare diseases. Prior to that, he served as vice president, worldwide marketing and other capacities with Pfizer, Inc. from 2002 to 2014 as senior director, marketing and business development with Bracco Diagnostics, a diagnostic pharmaceutical business with radiology and cardiology applications, from 1998-2002 and as director, business development of i-Stat, Inc., a medical device company, from 1995 to 1998. He holds a B.S. and M.Ed. from the University of Missouri and M.B.A. from the University of Chicago Booth School of Business.
高管简历
中英对照 | 中文 | 英文- Maria Maccecchini
Maria Maccecchini创立了Annovis，前身为QR Pharma，自2008年5月起担任总裁兼首席执行官。她曾担任Robin Hood Ventures公司（从2002年到2009年）、MidAtlantic Angel Group（从2005年到2009年）的两个天使集团的合伙人兼董事。她于1992年创立Symphony Pharmaceuticals/Annovis公司（生物技术公司，于2001年出售给Transgenomic公司），并担任首席执行官。在此之前，从1987年到1991年，她是Bachem Bioscience（瑞士Bachem AG的美国子公司，Mallinckrodt的分子生物学主管）的总经理。MacCecchini博士在加州理工学院（Caltech）和罗氏免疫学研究所（Roche Institute of Immunology）进行博士后研究。她获得了生物化学博士学位，来自巴塞尔生物中心，并在洛克菲勒大学获得了为期两年的访问奖学金。MacCecchini博士在生物技术公司、促进企业家精神的组织、国际贸易、妇女和慈善组织的几个董事会任职。她自2016年以来一直担任Wharton Business School的讲师。
Maria Maccecchini founded Annovis, formerly QR Pharma, and has served as President and CEO since May 2008. She was partner and director of two angel groups, Robin Hood Ventures, from 2002 to 2009 and MidAtlantic Angel Group, from 2005 to 2009. In 1992 she founded and became chief executive officer of Symphony Pharmaceuticals/Annovis, a biotech company, which was sold in 2001 to Transgenomic. Prior to that, from 1987 to 1991 she was General Manager of Bachem Bioscience, the US subsidiary of Bachem AG, Switzerland and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini conducted post-doctoral research at Caltech and the Roche Institute of Immunology. She earned a Ph.D. in biochemistry is from the Biocenter of Basel with a two-year visiting fellowship at The Rockefeller University. Dr. Maccecchini serves on several boards of biotechnology companies, organizations that promote entrepreneurship, international trade, women and charitable organizations. She has been a lecturer at Wharton Business School since 2016.- Maria Maccecchini创立了Annovis，前身为QR Pharma，自2008年5月起担任总裁兼首席执行官。她曾担任Robin Hood Ventures公司（从2002年到2009年）、MidAtlantic Angel Group（从2005年到2009年）的两个天使集团的合伙人兼董事。她于1992年创立Symphony Pharmaceuticals/Annovis公司（生物技术公司，于2001年出售给Transgenomic公司），并担任首席执行官。在此之前，从1987年到1991年，她是Bachem Bioscience（瑞士Bachem AG的美国子公司，Mallinckrodt的分子生物学主管）的总经理。MacCecchini博士在加州理工学院（Caltech）和罗氏免疫学研究所（Roche Institute of Immunology）进行博士后研究。她获得了生物化学博士学位，来自巴塞尔生物中心，并在洛克菲勒大学获得了为期两年的访问奖学金。MacCecchini博士在生物技术公司、促进企业家精神的组织、国际贸易、妇女和慈善组织的几个董事会任职。她自2016年以来一直担任Wharton Business School的讲师。
- Maria Maccecchini founded Annovis, formerly QR Pharma, and has served as President and CEO since May 2008. She was partner and director of two angel groups, Robin Hood Ventures, from 2002 to 2009 and MidAtlantic Angel Group, from 2005 to 2009. In 1992 she founded and became chief executive officer of Symphony Pharmaceuticals/Annovis, a biotech company, which was sold in 2001 to Transgenomic. Prior to that, from 1987 to 1991 she was General Manager of Bachem Bioscience, the US subsidiary of Bachem AG, Switzerland and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini conducted post-doctoral research at Caltech and the Roche Institute of Immunology. She earned a Ph.D. in biochemistry is from the Biocenter of Basel with a two-year visiting fellowship at The Rockefeller University. Dr. Maccecchini serves on several boards of biotechnology companies, organizations that promote entrepreneurship, international trade, women and charitable organizations. She has been a lecturer at Wharton Business School since 2016.
- Jeffrey McGroarty
Jeffrey McGroarty自2019年4月以来一直是我们的首席财务官。在加入Annovis之前，McGroarty先生曾于2013年至2018年担任SafeguardScientifics，Inc.高级副总裁兼首席财务官。McGroarty先生于2005年加入Safeguard Scientifics，担任Vice President和公司财务总监，随后成为Vice President财务和公司财务总监，并于2012年至2013年担任高级副总裁财务总监。McGroarty先生于2005年担任Cephalon，Inc.临时财务总监；于2002年至2005年担任Exide Technologies财务规划与分析Vice President和助理财务总监；并于1991年至2001年担任普华永道会计师事务所临时财务总监。McGroarty先生在宾夕法尼亚州立大学（Pennsylvania State University）获得学士学位，在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得工商管理硕士学位。
Jeffrey McGroarty has been our Chief Financial Officer since April 2019. Prior to joining Annovis, Mr. McGroarty served as Senior Vice President and Chief Financial Officer of Safeguard Scientifics, Inc. from 2013 to 2018. Mr. McGroarty joined Safeguard Scientifics in 2005 as Vice President and Corporate Controller subsequently became Vice President-Finance and Corporate Controller, and served as Senior Vice President-Finance from 2012 to 2013. Mr. McGroarty served as Interim Controller of Cephalon, Inc. in 2005; Vice President-Financial Planning & Analysis and previously Assistant Controller at Exide Technologies from 2002 to 2005; and, previously, with PricewaterhouseCoopers from 1991 to 2001. Mr. McGroarty earned his Bachelor's degree from The Pennsylvania State University and his MBA from The Wharton School of The University of Pennsylvania.- Jeffrey McGroarty自2019年4月以来一直是我们的首席财务官。在加入Annovis之前，McGroarty先生曾于2013年至2018年担任SafeguardScientifics，Inc.高级副总裁兼首席财务官。McGroarty先生于2005年加入Safeguard Scientifics，担任Vice President和公司财务总监，随后成为Vice President财务和公司财务总监，并于2012年至2013年担任高级副总裁财务总监。McGroarty先生于2005年担任Cephalon，Inc.临时财务总监；于2002年至2005年担任Exide Technologies财务规划与分析Vice President和助理财务总监；并于1991年至2001年担任普华永道会计师事务所临时财务总监。McGroarty先生在宾夕法尼亚州立大学（Pennsylvania State University）获得学士学位，在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得工商管理硕士学位。
- Jeffrey McGroarty has been our Chief Financial Officer since April 2019. Prior to joining Annovis, Mr. McGroarty served as Senior Vice President and Chief Financial Officer of Safeguard Scientifics, Inc. from 2013 to 2018. Mr. McGroarty joined Safeguard Scientifics in 2005 as Vice President and Corporate Controller subsequently became Vice President-Finance and Corporate Controller, and served as Senior Vice President-Finance from 2012 to 2013. Mr. McGroarty served as Interim Controller of Cephalon, Inc. in 2005; Vice President-Financial Planning & Analysis and previously Assistant Controller at Exide Technologies from 2002 to 2005; and, previously, with PricewaterhouseCoopers from 1991 to 2001. Mr. McGroarty earned his Bachelor's degree from The Pennsylvania State University and his MBA from The Wharton School of The University of Pennsylvania.